{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee MY"],"funding":["Intramural NIH HHS","National Institutes of Health"],"pagination":["361-370"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8409092"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(4)"],"pubmed_abstract":["Owing to the presence of known tumor-specific viral antigens, human papillomavirus (HPV)-associated cancers are well suited for treatment with immunotherapy designed to unleash, amplify or replace the T cell arm of the adaptive immune system. Immune checkpoint blockade designed to unleash existing T cell immunity is currently Food and Drug Administration approved for certain HPV-associated cancers. More specific immunotherapies such as therapeutic vaccines and T cell receptor-engineered cellular therapy are currently in clinical development. Such therapies may offer more specific immune activation against viral tumor antigens and decrease the risk of immune-related adverse events. Current and planned clinical study of these treatments will determine their utility in the treatment of patients with newly diagnosed advanced stage or relapsed HPV-associated cancer."],"journal":["Seminars in radiation oncology"],"pubmed_title":["Immunotherapy for HPV Malignancies."],"pmcid":["PMC8409092"],"funding_grant_id":["ZIA DC000087"],"pubmed_authors":["Allen CT","Lee MY"],"additional_accession":[]},"is_claimable":false,"name":"Immunotherapy for HPV Malignancies.","description":"Owing to the presence of known tumor-specific viral antigens, human papillomavirus (HPV)-associated cancers are well suited for treatment with immunotherapy designed to unleash, amplify or replace the T cell arm of the adaptive immune system. Immune checkpoint blockade designed to unleash existing T cell immunity is currently Food and Drug Administration approved for certain HPV-associated cancers. More specific immunotherapies such as therapeutic vaccines and T cell receptor-engineered cellular therapy are currently in clinical development. Such therapies may offer more specific immune activation against viral tumor antigens and decrease the risk of immune-related adverse events. Current and planned clinical study of these treatments will determine their utility in the treatment of patients with newly diagnosed advanced stage or relapsed HPV-associated cancer.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-22T21:48:30.197Z","creation":"2025-02-19T01:27:17.545Z"},"accession":"S-EPMC8409092","cross_references":{"pubmed":["34455991"],"doi":["10.1016/j.semradonc.2021.02.008"]}}